预约演示
更新于：2025-07-05
Azelnidipine
阿折地平
更新于：2025-07-05
概要
基本信息
药物类型 小分子化药 |
别名 Azelnidipine (JP17/INN)、CS-905、RS 9054 + [5] |
作用方式 阻滞剂 |
作用机制 L-type calcium channel阻滞剂(L-型电压门控性钙通道家族阻滞剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2003-01-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C33H34N4O6 |
InChIKeyZKFQEACEUNWPMT-UHFFFAOYSA-N |
CAS号123524-52-7 |
关联
34
项与 阿折地平 相关的临床试验CTRI/2024/08/072999
Comparison of the Efficacy of 24 Hour BP Control of Azelnidipine, Amlodipine and Cilnidipine in Mild to Moderate Essential Hypertension – a Prospective Multi-centric Parallel Arm Real-world Study (AMCILAZ-EH Study) - AMCILAZ-EH Study
CTRI/2024/08/071803
Post-approval, case control analyses to assess clinical safety and effectiveness of Azelnidipine and Cilnidipine as initial -addon therapy in management of T2DM with HTN - HYDIAZ
CTRI/2024/07/071061
Post-approval, observational study to assess clinical safety and effectiveness of Azelnidipine and Telmisartan in management of Diabetic HTN - TELAZ
100 项与 阿折地平 相关的临床结果
登录后查看更多信息
100 项与 阿折地平 相关的转化医学
登录后查看更多信息
100 项与 阿折地平 相关的专利（医药）
登录后查看更多信息
536
项与 阿折地平 相关的文献（医药）2025-02-08JOURNAL OF CHROMATOGRAPHIC SCIENCE
An Analytical Approach by Tri-Combination of Gradient UFLC, Response Surface Methodology and Green Chemistry Principle for Simultaneous Quantification of Azelnidipine and Chlorthalidone in Rabbit Plasma
Article
作者: Ramesh, B ; Sahariah, Bhargab Jyoti ; Majumder, Manish ; Bhagyalakshmi, C ; Dutta, Koushik Nandan ; Longkumer, Piyongsola ; Rekha, T N
Abstract:
In this study, a sustainable and eco-friendly method is developed to quantify azelnidipine and chlorthalidone in rabbit plasma by gradient liquid chromatography based on green chemistry principle and analytical quality by design. The separation was achieved on a Shim pack C18 (25 cm × 5 cm × 4.6 μm) column with L1 packing. The mobile phase compromised of ethanol and 50-Mm ammonium acetate buffer (pH.6) at flow rate of 0.6 mL/min with 25-min runtime. The resolution and asymmetric factor were identified as critical analytical attributes (CAAs). The screening studies employing Control Noise Experimentation revealed that mobile phase pH, flow rate and ethanol concentration at 6 and 15 min significantly affected the CAAs method. The critical method parameters were optimized using Central Composition design. Chromatogram showed peak of the drugs at retention time of 9.03 min for chlorthalidone and 16.83 min for azelnidipine. The greenness score of the analytical method was found to be 1876.43 using analytical method greenness score calculator. The validation of the developed method was done which showed linearity at the range of 16–520 ng/mL, with R2 of 0.9992 and 0.9996 for azelnidipine and chlorthalidone, respectively, furthermore accuracy, precision, recovery and stability studies are carried out.
2024-12-01INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY
Stability indicating analytical method development and validation for azelnidipine and chlorthalidone by LC-MS method
作者: Nandhu, R. ; Gandhi, Meenal ; Sanjay, S. ; Manikandan, M. ; Tharik, A. Mohamed Sheik
An accurate, precise, and reproducible HPLC-MS-based stability-indicating was developed and validated for the simultaneous quantitative determination of Azelnidipine (AZL) and Chlorthalidone (CTE). HPLC-MS method employs an X Bridge C18 column (5 μm, 4.6 x 250 mm) and a mobile phase, 5mM Potassium dihydrogen phosphate: Acetonitrile (10:90 v/v) ratio with, pH 7.8 adjusted using Triethylamine, for the simultaneous determination of AZL and CTE. The detection was carried out at 261 nm with a flow rate of 1.0 ml/min. The method reveals linearity over the concentration ranges of 0.1-0.6 mcg/ml for AZL and 0.16-0.96 mcg/ml for CTE with correlation coefficients of 0.9901 and 0.9988, respectively. Precision (%RSD) for intraday analysis was found to be 0.98% for AZL and 0.88% for CTE. Accuracy was negotiated at three different concentrations, and the results indicated %Recovery within acceptable limits. Limits of detection and quantification were determined to be 52 ng/ml and 45.6 ng/ml for both compounds, respectively.. KEYWORDS :Azelnidipine, Chlorthalidone, LC-MS, Stability-Indicating method, Method development.
2024-12-01INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY
Stability Assessment through HPTLC for Concurrent Assessment of Azelnidipine and Telmisartan in Mass and Integrated Tablet Drug Formulation
作者: Jayashree, J. ; Mohan, S. ; Haribhuvanesh, P.
This study aims to estimate the stability assessment through HPTLC for the concurrent assessment of (±)3-(1-diphenylmethylazetidin-3-yl)5-isopropyl-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylate (Azelnidipine) and 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl] phenyl]benzoic acid (Telmisartan) in combined tablet formulation, a new HPTLC approach devised and validated that is simple, quick, precise, selective, and accurate stability suggesting. The adsorbent phase used is previously coated with a silica pack on TLC aluminum plates with 60F-254 using Chloroform: Ethyl acetate (5:5 v/v) of a total of 10 ml as the mobile phase. Both Azelnidipine (Rf 0.70) and Telmisartan (Rf 0.17), at 254 nm, densitometric scanning was performed in the reflectance absorptivity mode. In the linearity range of 1-6 μg/ml for Azelnidipine and 5-30 μg/ml for Telmisartan, the calibration graph demonstrated satisfactory linearity with r2 = 0.9967 and 0.9966, respectively. Azelnidipine and Telmisartan percentage assays were discovered to be 98.87 and 100.17. The percent RSD for intraday AZL and TLM experiments was 0.0184 and 0.0068. The percent RSD for AZL and TLM interday trials was discovered as 0.0126 and 0.0068. The LOD for AZL and TLM was discovered as 910 ng/mark and 4570 ng/mark. AZL and TLM were discovered to have LOQs of 2763 ng/mark and 13850 ng/mark, respectively. According to the ICH guidelines, drugs were exposed to acidic, basic, oxidative, photo, and heat-activated degradation. The medication degrades in acidic, basic, oxidative and heat environments but not in light or neutral environments (water). This procedure can be used to efficiently isolate the drug substance from its degradation products and this is used to indicate strength and stability.. KEYWORDS :Azelnidipine, Telmisartan, HPTLC, UV-visible spectroscopy, Validation, Stability studies.
1
项与 阿折地平 相关的新闻（医药）
100 项与 阿折地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 日本 | 2003-01-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 36 | 築齋廠齋齋鑰鹽憲製窪(鹹遞廠鏇範願觸鏇憲蓋) = 獵觸鬱顧網觸顧醖壓製 構窪淵鏇鬱蓋鏇窪衊醖 (窪餘選顧築窪觸鬱夢遞 ) | - | 2020-02-01 | |||
築齋廠齋齋鑰鹽憲製窪(鹹遞廠鏇範願觸鏇憲蓋) = 衊鹹選夢鹽範鑰願顧製 構窪淵鏇鬱蓋鏇窪衊醖 (窪餘選顧築窪觸鬱夢遞 ) | |||||||
N/A | - | 鑰襯簾膚憲鏇鑰淵衊鏇(顧襯網鬱觸糧鑰顧繭衊) = 鹽壓壓艱淵窪襯糧築選 蓋艱簾鬱遞顧淵顧膚鏇 (築願鬱鬱衊網願構鏇選 ) 更多 | 积极 | 2012-09-01 | |||
鑰襯簾膚憲鏇鑰淵衊鏇(顧襯網鬱觸糧鑰顧繭衊) = 選鬱觸膚繭蓋蓋衊夢廠 蓋艱簾鬱遞顧淵顧膚鏇 (築願鬱鬱衊網願構鏇選 ) 更多 | |||||||
N/A | - | 鑰鹹襯鬱壓蓋構憲蓋餘(廠齋範鏇廠鹹壓築襯構) = 顧衊餘範齋築選鏇艱築 夢壓積獵窪範遞鹽夢餘 (網餘夢衊壓顧簾鹽鹽遞, 5) 更多 | 积极 | 2010-06-01 | |||
鑰鹹襯鬱壓蓋構憲蓋餘(廠齋範鏇廠鹹壓築襯構) = 構窪襯鬱艱餘糧網糧襯 夢壓積獵窪範遞鹽夢餘 (網餘夢衊壓顧簾鹽鹽遞, 4) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用